Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF) Social Stream
CAN-FITE BIOPHARMA LTD (CANF) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering CAN-FITE BIOPHARMA LTD.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
Over the past 43 months, CANF's average price target has gone up $10.33.
CANF reports an average of 666.25% for its upside potential over the past 39 weeks.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
CANF Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
CANF's average broker recommendation rating improved by 0 over the prior 24 months.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- CANF has a greater number of analysts covering the stock than 18.36% of all US stocks.
- CAN-FITE BIOPHARMA LTD's variance in analysts' estimates is lower than -146.87% of all US stocks.
- In the context of stocks in the micro market cap category, CAN-FITE BIOPHARMA LTD's average analyst price target is higher than 393.83% of them.
- In the context of Healthcare stocks, CAN-FITE BIOPHARMA LTD's upside potential (average analyst target price relative to current price) is higher than 451.32% of them.
In the Pharmaceutical Products industry, BLRX, GLMD, and EDSA are the three stocks most similar to CAN-FITE BIOPHARMA LTD regarding the price target and analyst recommendation information presented here.
Make investment decisions regarding CANF using the data that counts. Try POWR Ratings for free.